Nitric oxide Inhibitors
1 drugsAbout Nitric oxide
Nitric oxide (NO) is a simple molecule involved in various biological processes. It plays a crucial role in key physiological functions, making it a potential drug target.
Currently, there is no genetic evidence directly linking nitric oxide to specific diseases. However, pharmaceuticals have been developed to modulate its activity, primarily in cardiovascular health.
BIDIL is the only FDA-approved drug targeting nitric oxide, formulated as a small molecule. AZURITY is the sole company with an approved drug in this area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Basal Cell Carcinoma with only 1 trials.
Top Nitric oxide Drugs
AZURITY is the only company with an approved drug targeting nitric oxide.
Low competition suggests an opportunity for new entrants, but also highlights potential challenges.
Nitric oxide Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Nitric oxide, using small molecule modality.
Explore alternative modalities like biologics to differentiate from existing therapies.
Nitric oxide Clinical Trials 6 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 3 | 3 | 0 | 0 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Nitric oxide Drug Approval Timeline (2005 - 2005)
The first and most recent drug approval was BIDIL in 2005.
The lack of recent approvals indicates a potentially saturated market or challenges in developing new therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 13 clinical trials targeting Nitric oxide.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities